Biotech stocks have been on a roller-coaster ride, but continue to outperform the broader market.
In 2021, the industry was thrust into the pandemic limelight as Pfizer (PFE) and its partner BioNTech (BNTX), Moderna (MRNA) and Johnson & Johnson (JNJ) launched a trio of Covid vaccines. But as society learned to live with Covid — and other concerns around the economy, inflation and politics took center stage — interest in biotech fell by the wayside. Shares of Investor's Business Daily's biotech industry group largely declined for 16 months.
Until now.
After hitting a six-year low in mid-June, biotech stocks seem to have regained their footing. Shares rose 40% from that point through mid-August, before tapering slightly down. But the slight decline comes amid a steeper dive for the broader market. The group is ranked sixth out of 197 industry groups tracked by Investor's Business Daily. Meanwhile, the pharma group ranks No. 129.
"The sector has started to show signs of a rebound, and we believe several key data events in the coming months as well as any pickup in (mergers and acquisitions), will likely be pivotal in determining whether investor risk appetite will increase and help sustain the recovery," RBC Capital Markets analyst Brian Abrahams said in a recent report.
But it's key to watch specific measures when examining stocks. In terms of fundamental and technical measures as well as 12-month performance, the best biotech stocks today are:
Catalyst Pharmaceuticals (CPRX)
Vertex Pharmaceuticals (VRTX)
Genmab (GMAB)
Neurocrine Biosciences (NBIX)
Supernus Pharmaceuticals (SUPN)
The No. 1 Biotech Stock
Catalyst is the No. 1 biotech stock, leading an industry group of more than 800 companies.
Its only product is Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, or LEMS. LEMS is a rare autoimmune condition that saps muscle strength and often occurs in lung cancer patients.
Though sales are growing, the company is looking to acquire a second or third product — either through an outright buyout or licensing deal.
Now, the biotech stock is extended above a cup base with a buy point at 8.74, MarketSmith.com shows.
Catalyst shares are also on the Tech Leaders list.
Bullishly, CPRX shares have a best-possible Composite Rating of 99, according to IBD Digital. This puts the biotech stock in the top 1% of all stocks in terms of fundamental and technical measures. Its 12-month performance, measured by the Relative Strength Rating, is also in the top 1% of all stocks.
Moving Beyond Cystic Fibrosis
Vertex is one of the biggest biotech stocks in terms of market cap. It ranks fourth behind Amgen (AMGN), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN).
The company is the de facto leader of the cystic fibrosis drug market. Second-quarter sales — dominated by its triple regimen Trikafta — jumped 22% to almost $2.2 billion.
But it's now expanding into other efforts. Vertex is partnered with Crispr Therapeutics (CRSP) on a gene-editing approach to a pair of blood diseases. Further, Vertex recently announced its $320 million plan to buy its partner in diabetes treatment, privately held ViaCyte. The companies are testing a cell replacement drug in type 1 diabetes.
Beyond that, Vertex is testing treatments for liver and kidney diseases, Duchenne muscular dystrophy and pain.
The biotech stock has a perfect Composite Rating and a Relative Strength Rating of 95. But shares are now sitting just below their 50-day moving average.
The company is also a Tech Leader.
Cancer Treatments Are Key
Genmab sells a small handful of treatments for cancer. The company partners with big biopharma names, including AbbVie (ABBV), Johnson & Johnson (JNJ), Horizon Therapeutics (HZNP) and Seagen (SGEN).
In the second quarter, adjusted earnings and sales increased bullishly to 40 cents per share and $440 million, respectively. Both measures also easily topped forecasts.
Now, Genmab on expanding its suite of medicines to new solid tumors and blood cancers.
Shares have a perfect Composite Rating of 98 and a Relative Strength Rating of 73. Genmab is also a Tech Leader.
Gaining Pipeline Recognition
Biotech stock investors are watching catalysts galore for Neurocrine Bio in the second half of 2022 and next year. The company sells a movement disorder treatment called Ingrezza. Ingrezza brought in $350 million in net sales in the second quarter, growing by double digits and beating forecasts.
Neurocrine also raised its Ingrezza sales expectations for the year to $1.35 billion to $1.4 billion.
Meanwhile, the company has a number of drugs in the works for schizophrenia, depression and an adrenal disorder — to name just a few.
The biotech stock's relative strength line is at a 52-week high. Shares also have a promising Composite Rating of 97 and a Relative Strength Rating of 93. Neurocrine stock is forming a flat base with a buy point at 109.36.
Plus, NBIX shares land on the Tech Leaders list.
New Approach To ADHD
Supernus is best known for its migraine prevention drug, Trokendi, but biotech stock investors are also watching the growth trajectory for Qelbree. Qelbree is a non-stimulant treatment for attention deficit hyperactivity disorder, or ADHD. Regulators have approved it for people as young as 6.
In the June quarter, Qelbree prescriptions surged by a third to 62,938. Sales grew 34% to $11.1 million. That helped offset a 9% decline for Trokendi.
The company also is working on treatments for Parkinson's disease, treatment-resistant depression and epilepsy.
The biotech stock recently broke out of a lengthy double-bottom base with an entry at 34.55. Shares slid below their buy point in late August. Since then, they have bounded into and out of the 5% chase zone.
Supernus stock is also a Tech Leader.
There is another biotech stock that is worth to look at which is Regencell Bioscience, $RGC.
As an early-stage bioscience company, Regencell Bioscience is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
https://www.investors.com/news/technology/bio...g-hot-run/
In 2021, the industry was thrust into the pandemic limelight as Pfizer (PFE) and its partner BioNTech (BNTX), Moderna (MRNA) and Johnson & Johnson (JNJ) launched a trio of Covid vaccines. But as society learned to live with Covid — and other concerns around the economy, inflation and politics took center stage — interest in biotech fell by the wayside. Shares of Investor's Business Daily's biotech industry group largely declined for 16 months.
Until now.
After hitting a six-year low in mid-June, biotech stocks seem to have regained their footing. Shares rose 40% from that point through mid-August, before tapering slightly down. But the slight decline comes amid a steeper dive for the broader market. The group is ranked sixth out of 197 industry groups tracked by Investor's Business Daily. Meanwhile, the pharma group ranks No. 129.
"The sector has started to show signs of a rebound, and we believe several key data events in the coming months as well as any pickup in (mergers and acquisitions), will likely be pivotal in determining whether investor risk appetite will increase and help sustain the recovery," RBC Capital Markets analyst Brian Abrahams said in a recent report.
But it's key to watch specific measures when examining stocks. In terms of fundamental and technical measures as well as 12-month performance, the best biotech stocks today are:
Catalyst Pharmaceuticals (CPRX)
Vertex Pharmaceuticals (VRTX)
Genmab (GMAB)
Neurocrine Biosciences (NBIX)
Supernus Pharmaceuticals (SUPN)
The No. 1 Biotech Stock
Catalyst is the No. 1 biotech stock, leading an industry group of more than 800 companies.
Its only product is Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, or LEMS. LEMS is a rare autoimmune condition that saps muscle strength and often occurs in lung cancer patients.
Though sales are growing, the company is looking to acquire a second or third product — either through an outright buyout or licensing deal.
Now, the biotech stock is extended above a cup base with a buy point at 8.74, MarketSmith.com shows.
Catalyst shares are also on the Tech Leaders list.
Bullishly, CPRX shares have a best-possible Composite Rating of 99, according to IBD Digital. This puts the biotech stock in the top 1% of all stocks in terms of fundamental and technical measures. Its 12-month performance, measured by the Relative Strength Rating, is also in the top 1% of all stocks.
Moving Beyond Cystic Fibrosis
Vertex is one of the biggest biotech stocks in terms of market cap. It ranks fourth behind Amgen (AMGN), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN).
The company is the de facto leader of the cystic fibrosis drug market. Second-quarter sales — dominated by its triple regimen Trikafta — jumped 22% to almost $2.2 billion.
But it's now expanding into other efforts. Vertex is partnered with Crispr Therapeutics (CRSP) on a gene-editing approach to a pair of blood diseases. Further, Vertex recently announced its $320 million plan to buy its partner in diabetes treatment, privately held ViaCyte. The companies are testing a cell replacement drug in type 1 diabetes.
Beyond that, Vertex is testing treatments for liver and kidney diseases, Duchenne muscular dystrophy and pain.
The biotech stock has a perfect Composite Rating and a Relative Strength Rating of 95. But shares are now sitting just below their 50-day moving average.
The company is also a Tech Leader.
Cancer Treatments Are Key
Genmab sells a small handful of treatments for cancer. The company partners with big biopharma names, including AbbVie (ABBV), Johnson & Johnson (JNJ), Horizon Therapeutics (HZNP) and Seagen (SGEN).
In the second quarter, adjusted earnings and sales increased bullishly to 40 cents per share and $440 million, respectively. Both measures also easily topped forecasts.
Now, Genmab on expanding its suite of medicines to new solid tumors and blood cancers.
Shares have a perfect Composite Rating of 98 and a Relative Strength Rating of 73. Genmab is also a Tech Leader.
Gaining Pipeline Recognition
Biotech stock investors are watching catalysts galore for Neurocrine Bio in the second half of 2022 and next year. The company sells a movement disorder treatment called Ingrezza. Ingrezza brought in $350 million in net sales in the second quarter, growing by double digits and beating forecasts.
Neurocrine also raised its Ingrezza sales expectations for the year to $1.35 billion to $1.4 billion.
Meanwhile, the company has a number of drugs in the works for schizophrenia, depression and an adrenal disorder — to name just a few.
The biotech stock's relative strength line is at a 52-week high. Shares also have a promising Composite Rating of 97 and a Relative Strength Rating of 93. Neurocrine stock is forming a flat base with a buy point at 109.36.
Plus, NBIX shares land on the Tech Leaders list.
New Approach To ADHD
Supernus is best known for its migraine prevention drug, Trokendi, but biotech stock investors are also watching the growth trajectory for Qelbree. Qelbree is a non-stimulant treatment for attention deficit hyperactivity disorder, or ADHD. Regulators have approved it for people as young as 6.
In the June quarter, Qelbree prescriptions surged by a third to 62,938. Sales grew 34% to $11.1 million. That helped offset a 9% decline for Trokendi.
The company also is working on treatments for Parkinson's disease, treatment-resistant depression and epilepsy.
The biotech stock recently broke out of a lengthy double-bottom base with an entry at 34.55. Shares slid below their buy point in late August. Since then, they have bounded into and out of the 5% chase zone.
Supernus stock is also a Tech Leader.
There is another biotech stock that is worth to look at which is Regencell Bioscience, $RGC.
As an early-stage bioscience company, Regencell Bioscience is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
https://www.investors.com/news/technology/bio...g-hot-run/
